Immune checkpoint therapy can stimulate an anti-tumor response by restoring T cell function through complex interactions among immune checkpoint molecules, such as PD-1, its ligand (PD-L1), and cytotoxic T lymphocyte-associated protein (CTLA-4) [32]. This evidence concerns the gene CTLA4 and neoplasm.